ScholarIQanswers from OpenAlex
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
PaperCitations, authors & open-access status
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis have?
ScholarIQcitation count
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis has 462 citations in the OpenAlex counts ScholarIQ stores.
When was Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis published?
ScholarIQyear
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis has 2021 year in the ScholarIQ index.
What is the open-access status of Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis?
ScholarIQoa status
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis has bronze oa status in the ScholarIQ index.
What is the DOI of Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis?
ScholarIQdoi
The DOI for Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis is on the source record.
What is the PMID of Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis?
ScholarIQpmid
The PMID for Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis is on the source record.
What is the OpenAlex record for Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis?
ScholarIQopenalex
The OpenAlex for Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis is on the source record.